Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RDY vs IFN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RDY Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

RDY Overall Winner 6-Pillar Tally: RDY 5 – 0 IFN (1 Tie) Matrix Metrics: RDY 9 – 1 IFN

As of Nov 16, 2026, Dr. Reddy's Laboratories Limited (RDY) is the stronger overall head-to-head candidate over The India Fund, Inc. (IFN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RDY carries a Unified Composite Score of 34.7/100 (SELL) at $14.70 (31.6x Forward P/E, 9.1% operating margin), whereas IFN carries 29.1/100 (SELL) at $11.48 (N/M Forward P/E, N/A operating margin).

  • Defensive Composite Rating Caution: Although RDY compares more favorably head-to-head, both RDY (34.7/100 SELL) and IFN (29.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RDY vs IFN
RDY NYSE Head-to-Head Winner
Dr. Reddy's Laboratories Limited American Depositary Shares
Pharmaceutical Preparations
$14.70
-0.27% 1D
Market Cap $12.3B
TTM Revenue $3.53B
Forward P/E 31.6x
Beta / 30D Vol 0.39β · 24% Vol
Unified Composite Score
34.7 / 100 SELL
Tech 17.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 68
RSI-14: 68.3 · SMA20: $14.22 · SMA50: $13.10
IFN NYSE
The India Fund, Inc.
Institutional Equity
$11.48
+0.17% 1D
Market Cap $593.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.68β · 20% Vol
Unified Composite Score
29.1 / 100 SELL
Tech 5.0 Fund 33.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 70
RSI-14: 69.8 · SMA20: $10.86 · SMA50: $10.80

6-Pillar Scorecard Institutional Category Breakdown (RDY 5 – 0 IFN)

Columns: Metric · RDY · IFN
1. Valuation Multiples RDY
Forward P/E 31.6x N/M
Trailing P/E 40.9x N/M
PEG Ratio 2.01x N/M
EV / Revenue 3.5x N/M
2. Growth & Scale RDY
Revenue Growth (YoY) -1.5% N/A
Earnings Growth (YoY) -35.7% N/A
TTM Revenue (USD) $3.53B N/A
Market Cap $12.3B $593.5M
3. Profitability & Quality RDY
Gross Margin 49.5% N/A
Operating Margin 9.1% N/A
Net Profit Margin 8.5% N/A
Return on Equity (ROE) 7.3% N/A
4. Balance Sheet & Cash Flow RDY
Cash Generation (TTM) $534M EBITDA N/A
Cash Flow Margin 15.1% EBITDA Mgn N/A
Net Cash / Leverage $0.82 Book/Sh · 7.3% ROE N/A ROE
Dividend Yield 0.57% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RDY
OpEx & R&D Intensity 40.4% of Rev ($1.43B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RDY (9) vs IFN (1)
Institutional Metric RDY IFN Criterion Row Edge
Market Capitalization
Scale
$12.3B $593.5M Larger Scale RDY
Trailing P/E Ratio
Valuation
40.9x N/M Lower Multiple RDY
Forward P/E Ratio
Valuation
31.6x N/M Lower Multiple RDY
Revenue Growth (YoY)
Growth
-1.5% N/A Higher Growth RDY
Operating Margin (TTM)
Profitability
9.1% N/A Higher Margin RDY
Net Profit Margin
Profitability
8.5% N/A Higher Margin RDY
Return on Equity (ROE)
Capital Efficiency
7.3% N/A Higher ROE RDY
52-Week Range Position
Momentum
78% ($11–$16) 26% ($10–$15) Stronger Trend RDY
Beta / 30D Volatility
Risk Regime
0.39β · 24% Vol 0.68β · 20% Vol Lower Realized Risk IFN
Unified Institutional Score
Composite Signal
34.7 / 100 (SELL) 29.1 / 100 (SELL) Higher Composite RDY
Trailing 12M Revenue (USD)
Operating Scale
$3.53B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
49.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.01x PEG · 3.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$534M EBITDA ($0.82 Book/Sh · 7.3% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RDY +3.86 pp
RDY: +12.47% · IFN: +8.61%
3M Horizon RDY +23.62 pp
RDY: +20.99% · IFN: -2.63%
6M Horizon RDY +8.95 pp
RDY: +8.09% · IFN: -0.86%
1Y Horizon RDY +29.9 pp
RDY: +5.98% · IFN: -23.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RDY vs IFN. Trailing 12-month operating profitability (RDY 9.1% vs IFN N/A) and valuation multiples (RDY 31.6x vs IFN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RDY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.53B
Gross Margin49.5%
Op. Margin9.1%
ROE / Fwd P/E7.3% · 31.6x
IFN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RDY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RDY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IFN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IFN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RDY Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $12.3B market capitalization and 9.1% operating margin.
OpEx & R&D Reinvestment 40.4% of Rev ($1.43B)
90D Engineering Disclosures 0 Published
IFN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $593.5M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RDY vs IFN Key Questions & Quantitative Answers

As of Nov 16, 2026, Dr. Reddy's Laboratories Limited (RDY) is the stronger overall head-to-head candidate over The India Fund, Inc. (IFN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RDY carries a Unified Composite Score of 34.7/100 (SELL) at $14.70 (31.6x Forward P/E, 9.1% operating margin), whereas IFN carries 29.1/100 (SELL) at $11.48 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although RDY compares more favorably head-to-head, both RDY (34.7/100 SELL) and IFN (29.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

RDY leads the Growth & Scale pillar: RDY posts -1.5% YoY revenue growth and -35.7% YoY earnings growth on $3.53B TTM revenue (49.5% gross margin, 9.1% operating margin), compared with IFN at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, RDY generates $3.53B in USD-normalized revenue versus N/A for IFN. In operating R&D and SG&A reinvestment, RDY deploys 40.4% of Rev ($1.43B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IFN.

RDY screens cheaper on headline valuation multiples. RDY trades at 31.6x Forward P/E, 40.9x Trailing P/E, 2.01x PEG, and 3.5x EV/Revenue (15.1% EBITDA margin), whereas IFN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RDY (7.3% ROE) versus IFN (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, RDY carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 24% Vol realized risk). By comparison, IFN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 20% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.